novartis ag fda extends right to sell medication for pediatric use novartis ag said it received an additional six months pediatric exclusivity in the u s for its high blood pressure medicine diovan the medication is the swiss pharmaceutical companys top selling drug with world wide sales of &# billion in the years first half diovan or valsartan has been granted marketing exclusivity by the food and drug administration based on studies conducted with children with high blood pressure the action extends marketing exclusivity associated with the valsartan compound patent by six months to september 
